Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SYNCHRONISE: Esomeprazole 20 mg Once Daily for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs in Dutch General Practice: The Influence of Risk-Factors for NSAID-Associated GI Damage on Sympton Response

NCT00524329 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00524329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00524329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SYNCHRONISE: Esomeprazole 20 mg Once Daily for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs in Dutch General Practice: The Influence of Risk-Factors for NSAID-Associated GI Damage on Sympton Response
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
January 31, 2006
Completion date
October 31, 2007
Enrollment
1,220 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

heartburn